|
|
Volumn 9, Issue 3, 2000, Pages 565-579
|
|
Therapeutic advances in small cell lung cancer
|
|
Author keywords
Apoptosis; bcl 2; BEC2; Experimental therapeutics; Immunotherapy; Metalloproteinases; Paclitaxel; Signal transduction; Small cell lung cancer; Substance P analogues; Topotecan
|
|
Indexed keywords
BRADYKININ ANTAGONIST;
CARBOPLATIN;
CHLORMETHINE;
CISPLATIN;
COMPLEMENTARY DNA;
CYCLOPHOSPHAMIDE;
DNA TOPOISOMERASE INHIBITOR;
DOCETAXEL;
DOLASTATIN;
DOXORUBICIN;
EPIRUBICIN;
GEMCITABINE;
IFOSFAMIDE;
IRINOTECAN;
METHOTREXATE;
NAVELBINE;
NITROSOUREA;
NY 3460;
PACLITAXEL;
PROTEIN BCL 2;
PROTEIN KINASE INHIBITOR;
SUBSTANCE P DERIVATIVE;
TANOMASTAT;
TAXANE DERIVATIVE;
TOPOTECAN;
UNCLASSIFIED DRUG;
VINBLASTINE;
VINCA ALKALOID;
VINCRISTINE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
APOPTOSIS;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CELL DEATH;
CLINICAL TRIAL;
HUMAN;
LUNG CARCINOGENESIS;
LUNG SMALL CELL CANCER;
NONHUMAN;
PHASE 4 CLINICAL TRIAL;
PROGNOSIS;
REVIEW;
SIGNAL TRANSDUCTION;
SURVIVAL RATE;
SURVIVAL TIME;
|
|
EID: 0033999466
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.9.3.565 Document Type: Review |
|
Times cited : (32)
|
|
References (108)
|
